• We offer tailored partnerships to support and transform drug discovery.

    Every collaboration is a bespoke arrangement, meticulously designed to discover new compounds and targets in patient relevant disease models.

  • MIMETAS offers flexible fee-for-service solutions for therapy prioritization, optimization, and de-risking of compounds.

    As an extension of your team, MIMETAS provides the expertise and resources needed for effective research and development.

  • Our OrganoReady program is made for you when you need optimized assays for investigational toxicology.

    We guarantee OrganoReady performance according to specifications, in a fast and convenient sales transaction with a clear fee structure.

  • Giving you some food for thought. Read our blogs to learn more about 3D tissue culture, research backgrounds, developments, and its future outlook.
  • Get inspired by research done by our scientists, partners, and customers around the globe.

  • Learn about our mission, vision, the history of the company, and find out what we mean with MIMETAS-do.
open menu icon close menu icon
EN

Phase 2 funding of £1 million awarded by CRACK IT Challenges to develop TDAR-on-a-chip

Leiden, February 22, 2022 – The CRACK IT Challenges is a competition from the NC3Rs, aimed at funding collaborations between industry, academics, small and medium-sized enterprises. The goal of these projects is to develop innovative solutions into marketable products or services that will deliver 3Rs benefits: the replacement, refinement and reduction of animals in research.

Last February, our team of scientists, which includes Dr. Karla Queiroz and Dr. Michelle Brouwer, was awarded Phase 1 funding of £100,000 for the development of a humanin vitro T-cell dependent antibody response (TDAR) assay. We are proud to announce that this year, the team have been awarded funding of £1 million to deliver Phase 2 of the 2020 CRACK IT Challenges. Other consortium-members include:

  • Professor Jolanda de Vries, Tumor Immunology Radboud
  • Sofie Pattijn, ImmunXperts
  • Jan de Sonneville, Life Science Methods

Why TDAR-on-a-chip?

Their work is sponsored by Bayer AG, GSK, Merck Healthcare KGaA and Novartis Pharma AG, with the the aim of developing a human in vitro TDAR assay to assess the immune enhancement properties of immunomodulatory therapeutics during drug development. A robust in vitro human immune response assay could better predict clinical outcomes and reduce the number of animals used to assess immunotoxicity. 

Having previously carried out proof-of-concept studies during Phase 1, the team will now aim to develop tools to deliver a high-throughput human in vitro t-cell dependent antibody response assay for Phase 2.

Read more about the CRACK IT Challenges.



Contact us Sign up for our Newsletter

Cookies

May we use cookies?
Hi there! Thanks for visiting our website. We use cookies to keep track of our website statistics to optimize the user experience. We also use cookies for marketing purposes. You can set your preferences by selecting the options below. Terms of Use & Privacy Policy
Accept all
Accept selected
Decline all